LSTA FY2024 EPS Boosted by Brookline Capital Management

Lisata Therapeutics, Inc. (NASDAQ:LSTA) – Analysts at Brookline Capital Management raised their FY2024 earnings estimates for Lisata Therapeutics in a research note issued to investors on Wednesday, October 30th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will earn ($2.81) per share for the year, up from their previous estimate of ($2.95). The consensus estimate for Lisata Therapeutics’ current full-year earnings is ($2.97) per share. Brookline Capital Management also issued estimates for Lisata Therapeutics’ FY2025 earnings at ($2.88) EPS.

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Lisata Therapeutics in a report on Wednesday, September 18th.

Lisata Therapeutics Stock Up 11.7 %

Lisata Therapeutics stock opened at $3.16 on Friday. The stock has a market capitalization of $26.29 million, a PE ratio of -1.23 and a beta of 1.21. Lisata Therapeutics has a twelve month low of $2.05 and a twelve month high of $3.83. The company has a 50 day moving average of $2.96 and a 200-day moving average of $3.08.

Lisata Therapeutics (NASDAQ:LSTA) last issued its earnings results on Monday, August 12th. The company reported ($0.61) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.14. During the same quarter in the prior year, the company posted ($0.50) earnings per share.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP increased its holdings in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.21% of Lisata Therapeutics worth $60,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.